View in EDS HTML Full Text PDF Full Text

The effectiveness, safety and cost‐effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non‐inferiority trial.

Saved in:
Bibliographic Details
Title: The effectiveness, safety and cost‐effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non‐inferiority trial.
Authors: Thomas, Dennis (AUTHOR), Farrell, Michael (AUTHOR), McRobbie, Hayden (AUTHOR), Tutka, Piotr (AUTHOR), Petrie, Dennis (AUTHOR), West, Robert (AUTHOR), Siahpush, Mohammad (AUTHOR), Gartner, Coral (AUTHOR), Walker, Natalie (AUTHOR), Mendelsohn, Colin P. (AUTHOR), Hall, Wayne (AUTHOR), Paul, Christine (AUTHOR), Zwar, Nicholas (AUTHOR), Ferguson, Stuart G. (AUTHOR), Boland, Veronica C. (AUTHOR), Richmond, Robyn (AUTHOR), Doran, Christopher M. (AUTHOR), Shakeshaft, Anthony (AUTHOR), Mattick, Richard P. (AUTHOR), Courtney, Ryan J. (AUTHOR)
Source: Addiction. May2019, Vol. 114 Issue 5, p923-933. 11p. 2 Diagrams, 1 Chart.
Subjects: Advertising, Alkaloids, Carbon monoxide, Cost effectiveness, Drugs, Interviewing, Health outcome assessment, Patient compliance, Self-evaluation, Smoking cessation, Telephones, Social support, Randomized controlled trials, Treatment effectiveness, Disease prevalence, Adverse health care events, Varenicline
Geographic Terms: Australia
Abstract: Background and aims: Smoking cessation medications are effective, but often underutilized because of costs and side effects. Cytisine is a plant‐based smoking cessation medication with more than 50 years of use in central and eastern Europe. While cytisine has been found to be well‐tolerated and more effective than nicotine replacement therapy, direct comparisons with varenicline have not been conducted. This study evaluates the effectiveness, safety and cost‐effectiveness of cytisine compared with varenicline. Design Two‐arm, parallel group, randomized, non‐inferiority trial, with allocation concealment and blinded outcome assessment. Setting: Australian population‐based study. Participants: Adult daily smokers (n = 1266) interested in quitting will be recruited through advertisements and Quitline telephone‐based cessation support services. Intervention and comparator: Eligible participants will be randomized (1 : 1 ratio) to receive either cytisine capsules (25‐day supply) or varenicline tablets (12‐week supply), prescribed in accordance with the manufacturer's recommended dosing regimen. The medication will be mailed to each participant's nominated residential address. All participants will also be offered standard Quitline behavioural support (up to six 10–12‐minute sessions). Measurements Assessments will be undertaken by telephone at baseline, 4 and 7 months post‐randomization. Participants will also be contacted twice (2 and 4 weeks post‐randomization) to ascertain adverse events, treatment adherence and smoking status. The primary outcome will be self‐reported 6‐month continuous abstinence from smoking, verified by carbon monoxide at 7‐month follow‐up. We will also evaluate the relative safety and cost‐effectiveness of cytisine compared with varenicline. Secondary outcomes will include self‐reported continuous and 7‐day point prevalence abstinence and cigarette consumption at each follow‐up interview. Comments If cytisine is as effective as varenicline, its lower cost and natural plant‐based composition may make it an acceptable and affordable smoking cessation medication that could save millions of lives world‐wide. [ABSTRACT FROM AUTHOR]
Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 135744243
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The effectiveness, safety and cost‐effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non‐inferiority trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Thomas%2C+Dennis%22">Thomas, Dennis</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Farrell%2C+Michael%22">Farrell, Michael</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22McRobbie%2C+Hayden%22">McRobbie, Hayden</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tutka%2C+Piotr%22">Tutka, Piotr</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Petrie%2C+Dennis%22">Petrie, Dennis</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22West%2C+Robert%22">West, Robert</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Siahpush%2C+Mohammad%22">Siahpush, Mohammad</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gartner%2C+Coral%22">Gartner, Coral</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Walker%2C+Natalie%22">Walker, Natalie</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mendelsohn%2C+Colin+P%2E%22">Mendelsohn, Colin P.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hall%2C+Wayne%22">Hall, Wayne</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Paul%2C+Christine%22">Paul, Christine</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zwar%2C+Nicholas%22">Zwar, Nicholas</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ferguson%2C+Stuart+G%2E%22">Ferguson, Stuart G.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Boland%2C+Veronica+C%2E%22">Boland, Veronica C.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Richmond%2C+Robyn%22">Richmond, Robyn</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Doran%2C+Christopher+M%2E%22">Doran, Christopher M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shakeshaft%2C+Anthony%22">Shakeshaft, Anthony</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mattick%2C+Richard+P%2E%22">Mattick, Richard P.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Courtney%2C+Ryan+J%2E%22">Courtney, Ryan J.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Addiction%22">Addiction</searchLink>. May2019, Vol. 114 Issue 5, p923-933. 11p. 2 Diagrams, 1 Chart.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Advertising%22">Advertising</searchLink><br /><searchLink fieldCode="DE" term="%22Alkaloids%22">Alkaloids</searchLink><br /><searchLink fieldCode="DE" term="%22Carbon+monoxide%22">Carbon monoxide</searchLink><br /><searchLink fieldCode="DE" term="%22Cost+effectiveness%22">Cost effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Drugs%22">Drugs</searchLink><br /><searchLink fieldCode="DE" term="%22Interviewing%22">Interviewing</searchLink><br /><searchLink fieldCode="DE" term="%22Health+outcome+assessment%22">Health outcome assessment</searchLink><br /><searchLink fieldCode="DE" term="%22Patient+compliance%22">Patient compliance</searchLink><br /><searchLink fieldCode="DE" term="%22Self-evaluation%22">Self-evaluation</searchLink><br /><searchLink fieldCode="DE" term="%22Smoking+cessation%22">Smoking cessation</searchLink><br /><searchLink fieldCode="DE" term="%22Telephones%22">Telephones</searchLink><br /><searchLink fieldCode="DE" term="%22Social+support%22">Social support</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trials%22">Randomized controlled trials</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+prevalence%22">Disease prevalence</searchLink><br /><searchLink fieldCode="DE" term="%22Adverse+health+care+events%22">Adverse health care events</searchLink><br /><searchLink fieldCode="DE" term="%22Varenicline%22">Varenicline</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Australia%22">Australia</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background and aims: Smoking cessation medications are effective, but often underutilized because of costs and side effects. Cytisine is a plant‐based smoking cessation medication with more than 50 years of use in central and eastern Europe. While cytisine has been found to be well‐tolerated and more effective than nicotine replacement therapy, direct comparisons with varenicline have not been conducted. This study evaluates the effectiveness, safety and cost‐effectiveness of cytisine compared with varenicline. Design Two‐arm, parallel group, randomized, non‐inferiority trial, with allocation concealment and blinded outcome assessment. Setting: Australian population‐based study. Participants: Adult daily smokers (n = 1266) interested in quitting will be recruited through advertisements and Quitline telephone‐based cessation support services. Intervention and comparator: Eligible participants will be randomized (1 : 1 ratio) to receive either cytisine capsules (25‐day supply) or varenicline tablets (12‐week supply), prescribed in accordance with the manufacturer's recommended dosing regimen. The medication will be mailed to each participant's nominated residential address. All participants will also be offered standard Quitline behavioural support (up to six 10–12‐minute sessions). Measurements Assessments will be undertaken by telephone at baseline, 4 and 7 months post‐randomization. Participants will also be contacted twice (2 and 4 weeks post‐randomization) to ascertain adverse events, treatment adherence and smoking status. The primary outcome will be self‐reported 6‐month continuous abstinence from smoking, verified by carbon monoxide at 7‐month follow‐up. We will also evaluate the relative safety and cost‐effectiveness of cytisine compared with varenicline. Secondary outcomes will include self‐reported continuous and 7‐day point prevalence abstinence and cigarette consumption at each follow‐up interview. Comments If cytisine is as effective as varenicline, its lower cost and natural plant‐based composition may make it an acceptable and affordable smoking cessation medication that could save millions of lives world‐wide. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=135744243
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/add.14541
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 923
    Subjects:
      – SubjectFull: Advertising
        Type: general
      – SubjectFull: Alkaloids
        Type: general
      – SubjectFull: Carbon monoxide
        Type: general
      – SubjectFull: Cost effectiveness
        Type: general
      – SubjectFull: Drugs
        Type: general
      – SubjectFull: Interviewing
        Type: general
      – SubjectFull: Health outcome assessment
        Type: general
      – SubjectFull: Patient compliance
        Type: general
      – SubjectFull: Self-evaluation
        Type: general
      – SubjectFull: Smoking cessation
        Type: general
      – SubjectFull: Telephones
        Type: general
      – SubjectFull: Social support
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Disease prevalence
        Type: general
      – SubjectFull: Adverse health care events
        Type: general
      – SubjectFull: Varenicline
        Type: general
      – SubjectFull: Australia
        Type: general
    Titles:
      – TitleFull: The effectiveness, safety and cost‐effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non‐inferiority trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Thomas, Dennis
      – PersonEntity:
          Name:
            NameFull: Farrell, Michael
      – PersonEntity:
          Name:
            NameFull: McRobbie, Hayden
      – PersonEntity:
          Name:
            NameFull: Tutka, Piotr
      – PersonEntity:
          Name:
            NameFull: Petrie, Dennis
      – PersonEntity:
          Name:
            NameFull: West, Robert
      – PersonEntity:
          Name:
            NameFull: Siahpush, Mohammad
      – PersonEntity:
          Name:
            NameFull: Gartner, Coral
      – PersonEntity:
          Name:
            NameFull: Walker, Natalie
      – PersonEntity:
          Name:
            NameFull: Mendelsohn, Colin P.
      – PersonEntity:
          Name:
            NameFull: Hall, Wayne
      – PersonEntity:
          Name:
            NameFull: Paul, Christine
      – PersonEntity:
          Name:
            NameFull: Zwar, Nicholas
      – PersonEntity:
          Name:
            NameFull: Ferguson, Stuart G.
      – PersonEntity:
          Name:
            NameFull: Boland, Veronica C.
      – PersonEntity:
          Name:
            NameFull: Richmond, Robyn
      – PersonEntity:
          Name:
            NameFull: Doran, Christopher M.
      – PersonEntity:
          Name:
            NameFull: Shakeshaft, Anthony
      – PersonEntity:
          Name:
            NameFull: Mattick, Richard P.
      – PersonEntity:
          Name:
            NameFull: Courtney, Ryan J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May2019
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 09652140
          Numbering:
            – Type: volume
              Value: 114
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Addiction
              Type: main
ResultId 1